Metabolic-Associated Steatotic Liver Disease

SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.